Related Experiment Video

Updated: Aug 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Phospholamban gene mutations are not associated with hypertrophic cardiomyopathy in a Northern Greek population

Theodora Kalemi1, Georgios Efthimiadis, Dimitrios Zioutas

  • 1Department of Biology and Genetics, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Biochemical Genetics
|December 31, 2005
PubMed

Insights

Genetic testing for hypertrophic cardiomyopathy (HCM) in Northern Greece found no mutations in the phospholamban (PLN) gene. This suggests PLN gene mutations are not associated with HCM in this specific population.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart condition with varied symptoms.
  • Over 250 mutations in 10 genes linked to sarcomeric proteins cause HCM.
  • Phospholamban (PLN) is a potential candidate gene for cardiomyopathy due to its role in calcium regulation.

Purpose of the Study:

  • To screen for mutations in the phospholamban (PLN) gene in patients with hypertrophic cardiomyopathy (HCM).
  • To investigate the association between PLN gene mutations and HCM in a Northern Greece population.

Main Methods:

  • Screened 53 consecutive HCM patients from Northern Greece for PLN gene mutations.
  • Utilized clinical evaluation, electrocardiography, and echocardiography for patient assessment.
  • Analyzed PCR products for mutations using restriction analysis and sequencing.

Main Results:

  • No mutations were detected in exons 1 and 2 of the phospholamban gene.
  • No mutations were found in the promoter region of the phospholamban gene.
  • No polymorphisms were identified in the screened PLN gene segments across all patients.

Conclusions:

  • Phospholamban (PLN) gene mutations were not found in this cohort of hypertrophic cardiomyopathy (HCM) patients from Northern Greece.
  • The study indicates that PLN gene mutations are not associated with HCM in the investigated Northern Greece population.
  • Further research may be needed to explore other genetic factors contributing to HCM in this region.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...